LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T CellsAeRyon Kim, Xin Yu, Andrew K. Sewell et al.|The Journal of Immunology|2019Cited by 45